https://mindmedicinelaw.com/briefing/epa-s-tsca-chemical-review-implications-for-psychedelics-20260610-11546The Psychedelic Journalen2026-06-10T22:04:18.636255+00:00EPA's TSCA Chemical Review: Implications for PsychedelicsEPA, TSCA, chemical review, psychedelic substances, regulatory compliance, market strategy, premanufacture notice, significant new use, microbial commercial activity, legal implicationshttps://mindmedicinelaw.com/briefing/nevada-expands-ketamine-program-in-mental-health-care-20260610-11838The Psychedelic Journalen2026-06-10T22:04:10.009051+00:00Nevada Expands Ketamine Program in Mental Health Careketamine program, interventional psychiatry, psychedelic-assisted therapy, mental health treatment, Nevada healthcare, clinical trials, psychedelic research, policy implications, patient access, treatment innovationhttps://mindmedicinelaw.com/briefing/optimi-health-s-psilocybin-export-to-uk-a-clinical-milestone-20260610-11837The Psychedelic Journalen2026-06-10T22:03:59.487627+00:00Optimi Health's Psilocybin Export to UK: A Clinical Milestonepsilocybin export, Optimi Health, UK Phase 2 trial, psychedelic research, international collaboration, regulatory frameworks, mental health treatments, clinical trials, therapeutic applications, market dynamicshttps://mindmedicinelaw.com/briefing/epa-s-snur-proposal-implications-for-psychedelic-research-20260610-11563The Psychedelic Journalen2026-06-10T15:06:41.610052+00:00EPA's SNUR Proposal: Implications for Psychedelic ResearchEPA, SNURs, TSCA, psychedelic research, chemical substances, regulatory compliance, manufacturing, processing, premanufacture notices, policy implicationshttps://mindmedicinelaw.com/briefing/psychedelics-and-adhd-systematic-review-highlights-research-gaps-20260610-11608The Psychedelic Journalen2026-06-10T15:06:30.332341+00:00Psychedelics and ADHD: Systematic Review Highlights Research Gapspsychedelics, ADHD treatment, systematic review, clinical trials, neuropsychiatric disorders, LSD, psilocybin, ketamine, serotonin receptors, psychedelic researchhttps://mindmedicinelaw.com/briefing/optimi-health-exports-psilocybin-for-uk-phase-2-trial-20260610-11686The Psychedelic Journalen2026-06-10T15:05:41.130938+00:00Optimi Health Exports Psilocybin for UK Phase 2 Trialpsilocybin export, Optimi Health, UK clinical trial, international collaboration, psychedelic research, regulatory framework, mental health treatment, Phase 2 trial, controlled substances, global healthcarehttps://mindmedicinelaw.com/briefing/gpcr-biased-signaling-new-frontiers-in-psychedelic-therapies-20260609-11609The Psychedelic Journalen2026-06-10T22:04:28.262478+00:00GPCR Biased Signaling: New Frontiers in Psychedelic TherapiesGPCR biased signaling, psychedelic therapies, drug development, clinical trials, serotonin receptor, mental health, pharmacology, regulatory frameworks, therapeutic innovation, signaling pathwayshttps://mindmedicinelaw.com/briefing/psychedelic-trials-methodology-faces-critical-review-20260609-11436The Psychedelic Journalen2026-06-09T15:03:58.478710+00:00Psychedelic Trials' Methodology Faces Critical Reviewpsychedelic trials, methodology scrutiny, clinical research, placebo controls, trial design, regulatory standards, psilocybin, MDMA, FDA approval, scientific integrityhttps://mindmedicinelaw.com/briefing/chicago-va-s-psilocybin-therapy-for-veterans-with-ptsd-20260609-11437The Psychedelic Journalen2026-06-09T15:03:46.616586+00:00Chicago VA's Psilocybin Therapy for Veterans with PTSDpsilocybin therapy, PTSD treatment, veterans mental health, psychedelic research, Chicago VA Hospital, psychiatric protocols, mental health care, clinical trials, psychedelic therapies, psychiatric treatmenthttps://mindmedicinelaw.com/briefing/n-acetylcysteine-in-ocd-treatment-promising-trial-results-20260608-11621The Psychedelic Journalen2026-06-10T15:06:05.307550+00:00N-acetylcysteine in OCD Treatment: Promising Trial Resultsn-acetylcysteine, obsessive-compulsive disorder, sertraline, clinical trial, adjunctive treatment, SSRI, glutamate modulation, Y-BOCS, placebo-controlled, cognitive functioninghttps://mindmedicinelaw.com/briefing/ketamine-vs-esketamine-depression-treatment-in-germany-20260608-11622The Psychedelic Journalen2026-06-10T15:05:53.086498+00:00Ketamine vs. Esketamine: Depression Treatment in Germanyketamine infusions, esketamine nasal spray, treatment-resistant depression, cost-effectiveness, German healthcare, clinical guidelines, psychedelic research, mental health policy, NMDA receptor, off-label usehttps://mindmedicinelaw.com/briefing/neuroinflammation-s-impact-on-treatment-resistant-depression-20260608-11510The Psychedelic Journalen2026-06-09T22:03:15.367776+00:00Neuroinflammation's Impact on Treatment-Resistant Depressiontreatment-resistant depression, neuroinflammation, personalized medicine, inflammatory markers, next-generation antidepressants, blood-brain barrier, major depressive disorder, immune system, mental health, biological subtypeshttps://mindmedicinelaw.com/briefing/meta-analysis-psychedelics-for-ptsd-treatment-20260608-11509The Psychedelic Journalen2026-06-09T22:02:58.037978+00:00Meta-Analysis: Psychedelics for PTSD TreatmentMDMA, PTSD, psychedelic-assisted psychotherapy, ketamine, cannabidiol, systematic review, meta-analysis, randomized controlled trials, efficacy, safetyhttps://mindmedicinelaw.com/briefing/psychedelics-in-hospital-psychiatry-future-directions-20260604-11643The Psychedelic Journalen2026-06-10T22:04:38.079521+00:00Psychedelics in Hospital Psychiatry: Future Directionspsychedelic treatments, hospital psychiatry, clinical trials, neuroplasticity, policy considerations, psychiatric care, psilocybin, MDMA, patient safety, therapeutic outcomeshttps://mindmedicinelaw.com/briefing/mdma-assisted-therapy-in-social-anxiety-disorder-trials-20260604-11496The Psychedelic Journalen2026-06-09T22:03:07.065122+00:00MDMA-Assisted Therapy in Social Anxiety Disorder Trialsmdma-assisted therapy, social anxiety disorder, clinical trials, psychedelics, mental health, treatment efficacy, neuroscience, public health, regulatory considerations, adverse eventshttps://mindmedicinelaw.com/briefing/ipa-s-depression-dementia-research-roadmap-future-directions-20260601-11582The Psychedelic Journalen2026-06-10T22:04:46.959250+00:00IPA's Depression-Dementia Research Roadmap: Future Directionsdepression, dementia, neurocognitive disorders, psychedelic therapies, biomarkers, precision psychiatry, caregiver burden, diagnostic criteria, multimodal interventions, brain healthhttps://mindmedicinelaw.com/briefing/ketamine-s-mechanisms-expand-beyond-nmda-antagonism-20260601-11684The Psychedelic Journalen2026-06-10T15:06:15.200768+00:00Ketamine's Mechanisms Expand Beyond NMDA Antagonismketamine, NMDA receptor, mental health treatment, neuroscience, clinical trials, psychedelic research, therapeutic potential, glutamate transmission, neurotransmitter systems